We are studying whether a new drug, lisaftoclax, combined with another treatment, helps patients with chronic lymphocytic leukemia who have been previously treated. The goal is to see if this combination improves survival and slows disease progression.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Lymphocytic Leukemia (CLL) and Small Cell Lymphocytic Lymphoma (SLL) are types of cancer that affect the blood and bone marrow, characterized by the accumulation of abnormal lymphocytes, leading to symptoms such as fatigue, swollen lymph nodes, and frequent infections.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
